Celyad SA (CYAD) Stock
CYAD is no longer traded. Celyad was delisted from the Nasdaq in July 2023.
Prices on this page are historical; the last trade was July 20, 2023 at $0.52.
Celyad stock price history
CYAD final trading statistics
- Final close
- $0.52
- Final trading day
- Jul 20, 2023
- Market cap at delisting
- $11.84M
- Shares outstanding
- 22.59M
- Final 52-week range
- $0.15 – $3.07
- Avg. volume (final 3 mo.)
- 11,204
- All-time high (split-adj.)
- $68.56 · Jun 2015
- All-time low (split-adj.)
- $0.15 · May 2023
- Return since IPO
- -99.2%
- Beta
- 1.69
- Book value / share
- $0.19
- Price / book
- 2.74
Celyad annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$40.9M | -$0.91 |
| FY2021 | $0.00 | -$26.5M | -$1.04 |
| FY2020 | $5.0K | -$17.5M | -$2.78 |
| FY2019 | $6.0K | -$28.6M | -$2.62 |
| FY2018 | $3.12M | -$37.4M | -$3.97 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Celyad SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Celyad stock FAQ
What happened to Celyad stock?
Celyad stock was delisted from the Nasdaq. Its final close was $0.52 on July 20, 2023.
Is CYAD stock still trading?
No. CYAD was delisted from the Nasdaq in July 2023 and no longer trades on a U.S. exchange.
What was the last price of CYAD stock?
CYAD closed at $0.52 on its final trading day, July 20, 2023, for a market value of about $11.84M.
What were Celyad's revenue and earnings in its last full fiscal year?
Celyad reported revenue of $0.00 and net income of -$40.9M in fiscal 2022, its last full year as a public company.
When did Celyad go public?
Celyad SA stock began trading on June 19, 2015.